Clinical trials: Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal Cancer
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice
This study is a multi-centre retrospective observational research study which will be conducted in UK centres with specialised liver surgical services.
- Trial name
- RESECT (NCT01460745)
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Colorectal Cancer, KRAS Gene Mutation
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
This is an expanded access program for eligible participants designed to provide access to onvansertib in combination with FOLFIRI and bevacizumab.
- Trial name
- NCT04446793
- Testing
- Onvansertib, Bevacizumab, FOLFIRI
- Sponsor
- Cardiff Oncology
Carcinoma, Hepatocellular, Metastatic Colorectal Cancer
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
- Trial name
- VEROnA (NCT03291379)
- Testing
- BTG-002814
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Boston Scientific Corporation
CRC
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
The study consists of the two parts, phase IIa and phase IIb.
- Trial name
- mCRC (NCT05233332)
- Testing
- HL-085, Vemurafenib
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Cachexia; Cancer, Cachexia
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm).
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 950 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Metastatic Colorectal Cancer
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
- Trial name
- NCT01927341
- Testing
- MEK162, Panitumumab
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Colorectal Neoplasms
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite…
- Trial name
- RELATIVITY-123 (NCT05328908)
- Testing
- Nivolumab-relatlimab FDC, Regorafenib, TAS-102
- Where
- 139 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Colorectal Cancer
Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated…
- Trial name
- ELEVATE CRC (NCT05330429)
- Testing
- Magrolimab, Bevacizumab, Irinotecan
- Where
- 51 sites in United States, Australia and 8 more
- Volunteers
- 77 people
- Sponsor
- Gilead Sciences
Metastatic Colorectal Cancer (mCRC)
A Clinical Study of Arfolitixorin in Patients With mCRC
This is a clinical research study taking place in Germany. Patients with colorectal cancer at a stage of the disease where metastases occur may take part in the study. A maximum of 90 people will participate in the study.
- Trial name
- NCT06922383
- Testing
- Arfolitixorin, Leucovorin
- Where
- 3 sites in Germany
- Volunteers
- 90 people
- Sponsor
- Isofol Medical AB
Metastatic Colorectal Cancer (mCRC)
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and…
- Trial name
- CLOVER (NCT06699836)
- Testing
- 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- CytoDyn, Inc.
Metastatic Colorectal Cancer
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
The purpose of this study was to assess whether the progression free survival (PFS) time with FOLFOX-4 plus cetuximab is longer than that with FOLFOX-4 alone as first-line treatment for mCRC in Chinese subjects with RAS wild-type…
- Trial name
- TAILOR (NCT01228734)
- Testing
- Cetuximab, Oxaliplatin, Folinic Acid
- Where
- 25 sites in China
- Volunteers
- 553 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Neoplasms
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to…
- Trial name
- NCT05141721
- Testing
- GRT-C901, GRT-R902, Atezolizumab
- Where
- 43 sites in United States
- Volunteers
- 700 people
- Sponsor
- Seattle Project Corporation
Metastatic Colorectal Cancer (mCRC)
Fruquintinib in Patients With Metastatic Colorectal Cancer
FRUQUENT is an observational study in Germany. The goal of the study is to evaluate how well Fruquintinib works to treat patients with metastatic colorectal cancer that have previously been treated with available standard…
- Trial name
- FRUQUENT (NCT06787105)
- Where
- 42 sites in Germany
- Volunteers
- 150 people
- Sponsor
- iOMEDICO AG
Colorectal Cancer
A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib…
- Trial name
- NCT07035886
- Testing
- No intervention
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Takeda
Solid Cancer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03890731
- Testing
- BAY73-4506 (Regorafenib, Stivarga)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 6 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment
The purpose of this this trial is to prove the efficacy and safety of MGN1703 as a maintenance therapy after first-line chemotherapeutic treatment of metastatic colorectal cancer.
- Trial name
- IMPALA (NCT02077868)
- Testing
- Usual Maintenance, MGN1703 treatment
- Where
- 125 sites in Austria, Belgium and 6 more
- Volunteers
- 540 people
- Sponsor
- Mologen AG
Metastatic Colorectal Cancer
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)
Open-label, dose-confirmation and cohort expansion, multicenter, Phase Ib/II study to assess the anti-tumor activity and safety of MEN1611 in combination with cetuximab for the treatment of participants with phosphatidylinositol…
- Trial name
- C-PRECISE-01 (NCT04495621)
- Testing
- MEN1611, Cetuximab
- Where
- 28 sites in United States, France and 5 more
- Volunteers
- 29 people
- Sponsor
- Menarini Group
Metastatic Colorectal Cancer
Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy
The purpose of this study is to evaluate the dose-limiting toxicity (DLT), toxicity profile, maximum tolerated dose (MTD) and characterize the pharmacokinetics of biweekly PEP02 treatment.
- Trial name
- NCT00940758
- Testing
- PEP02
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- PharmaEngine
Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
This was an open-label, phase Ib, multicenter clinical trial to determine the MTD/RDE of the orally administered c-MET inhibitor INC280 in combination with cetuximab.
- Trial name
- NCT02205398
- Testing
- INC280, cetuximab
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.
- Conditions
- Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)
- Trial name
- NCT07566897
- Testing
- L19IL2, Ruxolitinib
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- Philogen S.p.A.